These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 30826269)

  • 41. Hypertrophic Cardiomyopathy, Athlete's Heart, or Both: A Case of Hypertrophic Cardiomyopathy Regression.
    Kebed KY; Bos JM; Anavekar NS; Mulvagh SL; Ackerman MJ; Ommen SR
    Circ Cardiovasc Imaging; 2015 Jul; 8(7):e003312. PubMed ID: 26162782
    [No Abstract]   [Full Text] [Related]  

  • 42. Apical left ventricular hypertrophy and mid-ventricular obstruction in fabry disease.
    Cianciulli TF; Saccheri MC; Fernández SP; Fernández CC; Rozenfeld PA; Kisinovsky I
    Echocardiography; 2015 May; 32(5):860-3. PubMed ID: 25684266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.
    Hinojar R; Varma N; Child N; Goodman B; Jabbour A; Yu CY; Gebker R; Doltra A; Kelle S; Khan S; Rogers T; Arroyo Ucar E; Cummins C; Carr-White G; Nagel E; Puntmann VO
    Circ Cardiovasc Imaging; 2015 Dec; 8(12):. PubMed ID: 26659373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients.
    Senechal M; Germain DP
    Clin Genet; 2003 Jan; 63(1):46-52. PubMed ID: 12519371
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy.
    Hoigné P; Attenhofer Jost CH; Duru F; Oechslin EN; Seifert B; Widmer U; Frischknecht B; Jenni R
    Int J Cardiol; 2006 Aug; 111(3):413-22. PubMed ID: 16307805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rare presentation of Fabry disease as 'burnt-out' hypertrophic cardiomyopathy.
    Williams S; El-Medany A; Nightingale A; Ismail Y
    BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479887
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy.
    Kampmann C; Wiethoff CM; Martin C; Wenzel A; Kampmann R; Whybra C; Miebach E; Beck M
    Acta Paediatr Suppl; 2002; 91(439):21-7. PubMed ID: 12572838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Awareness of Fabry disease in cardiology: A gap to be filled.
    Brito D; Cardim N; Lopes LR; Belo A; Mimoso J; Gonçalves L; Madeira H;
    Rev Port Cardiol (Engl Ed); 2018 Jun; 37(6):457-466. PubMed ID: 29801713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Left ventricular hypertrophy: do not forget Fabry disease. Diagnostic work-up and differential diagnosis.
    Paelinck BP; Bondue A; Robyns T; Eyskens F
    Acta Cardiol; 2024 Aug; 79(6):642-649. PubMed ID: 38869089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An expert consensus document on the management of cardiovascular manifestations of Fabry disease.
    Linhart A; Germain DP; Olivotto I; Akhtar MM; Anastasakis A; Hughes D; Namdar M; Pieroni M; Hagège A; Cecchi F; Gimeno JR; Limongelli G; Elliott P
    Eur J Heart Fail; 2020 Jul; 22(7):1076-1096. PubMed ID: 32640076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body.
    Oikawa M; Sakamoto N; Kobayashi A; Suzuki S; Yoshihisa A; Yamaki T; Nakazato K; Suzuki H; Saitoh S; Kiko Y; Nakano H; Hayashi T; Kimura A; Takeishi Y
    BMC Cardiovasc Disord; 2016 May; 16():83. PubMed ID: 27160240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Fabry disease: An overlooked diagnosis in adult cardiac patients].
    Kayıkçıoğlu M; Şimşek E; Kalkan Uçar S; Bayraktaroğlu S; Onay H; Sözmen E; Çoker M
    Turk Kardiyol Dern Ars; 2017 Sep; 45(6):549-555. PubMed ID: 28902648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Physiologic or pathologic hypertrophy: how can we know?
    Lai EJ; Rakowski H
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):919-22. PubMed ID: 24972675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of Fabry Disease cardiac involvement according to longitudinal strain, cardiometabolic exercise test, and T1 mapping.
    Réant P; Testet E; Reynaud A; Bourque C; Michaud M; Rooryck C; Goizet C; Lacombe D; de-Précigout V; Peyrou J; Cochet H; Lafitte S
    Int J Cardiovasc Imaging; 2020 Jul; 36(7):1333-1342. PubMed ID: 32385539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fabry disease--a primer for cardiologists.
    Mursă A; Ginghină C; Jurcut R
    Rom J Intern Med; 2014; 52(4):216-22. PubMed ID: 25726623
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Late gadolinium enhancement image masquerading as hypertrophic cardiomyopathy in Fabry disease receiving enzyme replacement therapy.
    Yano T; Oshima H; Miki T; Tanaka M; Muranaka A; Osanami A; Takahashi F; Miura T
    Int J Cardiol; 2016 Jan; 203():136-7. PubMed ID: 26512827
    [No Abstract]   [Full Text] [Related]  

  • 58. Fabry disease and cardiovascular involvement.
    Anastasakis A; Papatheodorou E; Steriotis AK
    Curr Pharm Des; 2013; 19(33):5997-6008. PubMed ID: 23448453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
    Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
    Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiac magnetic resonance imaging illustrating Anderson-Fabry disease progression.
    Imbriaco M; Messalli G; Avitabile G; Cuocolo A; Maurea S; Soscia F; Pisani A
    Br J Radiol; 2010 Dec; 83(996):e249-51. PubMed ID: 21088081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.